Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
51°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
969.97
+11.33 (+1.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
September 11, 2023
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care....
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
New to Investing? Here's How You Can Get Started With $500.
September 10, 2023
You don't have to invest a lot to start building a winning portfolio.
Via
The Motley Fool
3 Unstoppable Growth Stocks to Buy Right Now
September 09, 2023
These healthcare stocks show no signs of slowing down.
Via
The Motley Fool
Check Out What Whales Are Doing With REGN
September 08, 2023
Via
Benzinga
2 Top Biotech Stocks to Buy in September
September 08, 2023
There is rarely a bad time to buy stocks with massive upside potential.
Via
The Motley Fool
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,000 Today
September 05, 2023
Via
Benzinga
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
August 30, 2023
Via
Benzinga
Check Out What Whales Are Doing With REGN
August 25, 2023
Via
Benzinga
Is Regeneron Stock a Buy Now?
August 25, 2023
The company's growth fuel isn't running out yet.
Via
The Motley Fool
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
September 05, 2023
Novartis expects to submit regulatory applications for its biosimilar soon.
Via
The Motley Fool
Is REGENERON PHARMACEUTICALS (NASDAQ:REGN) suited for quality investing?
September 01, 2023
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN)
Via
Chartmill
Small Cancer Therapy Player Celularity To Provide Research Support For Regeneron's Therapy
August 29, 2023
Celularity Inc (NASDAQ: CELU) shares are trading higher after the company announced a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals Inc (NASDAQ: REGN).
Via
Benzinga
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
August 28, 2023
An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.
Via
The Motley Fool
These Are the ONLY 7 Penny Stocks to Consider in August 2023
August 26, 2023
These are just a few of the most promising penny stocks to consider as we head into the final months of the year.
Via
InvestorPlace
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
August 22, 2023
Via
Benzinga
18 Analysts Have This to Say About Regeneron Pharmaceuticals
August 16, 2023
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $5,400 Today
August 15, 2023
Via
Benzinga
This Is What Whales Are Betting On Regeneron Pharmaceuticals
August 14, 2023
Via
Benzinga
Could This Medicine Be the Next Winner for Novartis?
August 23, 2023
The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials.
Via
The Motley Fool
Top 5 Health Care Stocks That May Fall Off A Cliff
August 23, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Regeneron Awarded $326M Government Contract For COVID-19 Antibody Therapy Development
August 22, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was awarded a government contract valued at up to $326 million on Tuesday.
Via
Benzinga
Exposures
COVID-19
Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition?
August 21, 2023
Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema,
Via
Benzinga
Exposures
Product Safety
Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed
August 21, 2023
The Vanguard Value Index Fund ETF (ARCA: VTV) has beaten the Vanguard Growth Index Fund ETF (ARCA: VUG) by 5% during the past month. The momentum shift comes as investors recalibrate their strategies...
Via
Benzinga
Topics
ETFs
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
August 21, 2023
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years.
Via
Talk Markets
FDA Approves Regeneron's Drug For Ultra Rare Immune Disorder
August 21, 2023
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Veopoz (pozelimab-bbfg) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient
Via
Benzinga
Exposures
Product Safety
Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms
August 21, 2023
The FDA signed off on Regeneron's high-dose Eylea about two months earlier than expected.
Via
Investor's Business Daily
Exposures
Product Safety
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
August 21, 2023
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),
Via
Benzinga
Exposures
Product Safety
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
August 21, 2023
The biotech's focus on innovation could be a boon for shareholders.
Via
The Motley Fool
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
August 14, 2023
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease.
Via
Investor's Business Daily
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
August 11, 2023
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.